In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: Investigation of the single-pass vs. the Doluisio experimental approaches

International Journal of Pharmaceutics

Volumn 480, Issue 1-2, 2015, Pages 1-7

  Lozoya Agullo, Isabel ^a,b   Zur, Moran ^c   Wolk, Omri ^c   Beig, Avital ^c   González Álvarez, Isabel ^a   González Álvarez, Marta ^a   Merino Sanjuán, Matilde ^b,d   Bermejo, Marival ^a   Dahan, Arik ^c  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

Bioequivalence; Biopharmaceutics classification system; Biowaiver; Intestinal permeability; Oral drug absorption; Perfusion study

Indexed keywords

ATENOLOL; CAFFEINE; CARBAMAZEPINE; CHLORAMPHENICOL; CIMETIDINE; CODEINE; COLCHICINE; DIGOXIN; FUROSEMIDE; IBUPROFEN; LABETALOL; METOPROLOL; PARACETAMOL; PHENAZONE; VALSARTAN; DRUG;

ARTICLE; BIOPHARMACEUTICS CLASSIFICATION SYSTEM; DRUG PENETRATION; HUMAN; INTESTINE PERFUSION; MALE; NONHUMAN; PHARMACEUTICS; PREDICTION; PRIORITY JOURNAL; RAT; ANIMAL; BIOLOGICAL MODEL; CLASSIFICATION; COMPARATIVE STUDY; INTESTINE; INTESTINE ABSORPTION; METABOLISM; PERFUSION; PERMEABILITY; PROCEDURES; WISTAR RAT;

ANIMALS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MALE; MODELS, BIOLOGICAL; PERFUSION; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; RATS; RATS, WISTAR;

EID: 84922318685     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.01.014     Document Type: Article

References (58)

1. G. Amidon, P. Sinko, and D. Fleisher Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds Pharm. Res. 5 1988 651 654
2. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
3. K.S. Amidon, P. Langguth, H. Lennernas, L. Yu, and G.L. Amidon Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy Clin. Pharmacol. Ther. 90 2011 467 470
4. A. Beig, J.M. Miller, and A. Dahan Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption Eur. J. Pharm. Biopharm. 2012 81
5. M. Bermejo, V. Merino, T. Garrigues, J. Pla Delfina, A. Mulet, P. Vizet, G. Trouiller, and C. Mercier Validation of a biophysical drug absorption model by the PATQSAR system J. Pharm. Sci. 88 1999 398 405
6. X. Cao, L.X. Yu, C. Barbaciru, C.P. Landowski, H.-C. Shin, S. Gibbs, H.A. Miller, G.L. Amidon, and D. Sun Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability Mol. Pharm. 2 2005 329 340
7. X. Cao, S. Gibbs, L. Fang, H. Miller, C. Landowski, H. Shin, H. Lennernäs, Y. Zhong, G. Amidon, L. Yu, and D. Sun Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model Pharm. Res. 23 2006 1675 1686
8. V. Casabó, E. Núñez-Benito, A. Martínez-Coscollá, E. Miralles-Loyola, A. Martín-Villodre, and J. Plá-Delfina Studies on the reliability of a bihyperbolic functional absorption model: II. Phenylalkylamines J. Pharmacokinet. Biopharm. 15 1987 633 643
9. CDER/FDA, 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release dosage forms based on a biopharmaceutical slassification system. Center for Drug Evaluation and Research.
10. A. Dahan, and G. Amidon Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of P-gp Pharm. Res. 26 2009 883 892
11. A. Dahan, and G.L. Amidon Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs Mol. Pharm. 6 2009 19 28
12. A. Dahan, and G.L. Amidon MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting Int. J. Pharm. 386 2010 216 220
13. A. Dahan, and J. Miller The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs AAPS J. 14 2012 244 251
14. A. Dahan, J.M. Miller, and G.L. Amidon Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs AAPS J. 11 2009 740 746
15. A. Dahan, H. Sabit, and G. Amidon The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport AAPS J. 11 2009 205 213
16. A. Dahan, H. Sabit, and G.L. Amidon Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-gp and MRP2 leads to decreased intestinal absorption throughout the entire small intestine Drug Metab. Dispos. 37 2009 2028 2036
17. A. Dahan, B.T. West, and G.L. Amidon Segmental-dependent membrane permeability along the intestine following oral drug administration: evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat Eur. J. Pharm. Sci. 36 2009 320 329
18. A. Dahan, J.M. Miller, J.M. Hilfinger, S. Yamashita, L.X. Yu, H. Lennernaös, and G.L. Amidon High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations Mol. Pharm. 7 2010 1827 1834
19. A. Dahan, H. Lennernas, and G.L. Amidon The fraction dose absorbed, in humans, and high jejunal human permeability relationship Mol. Pharm. 9 2012 1847 1851
20. A. Dahan, O. Wolk, Y.H. Kim, C. Ramachandran, G.M. Crippen, T. Takagi, M. Bermejo, and G.L. Amidon Purely in silico BCS classification: science based quality standards for the world's drugs Mol. Pharm. 10 2013 4378 4390
21. J.T. Doluisio, N.F. Billups, L.W. Dittert, E.T. Sugita, and J.V. Swintosky Drug absorption I: an in situ rat gut technique yielding realistic absorption rates J. Pharm. Sci. 58 1969 1196 1200
22. J.T. Doluisio, G.H. Tan, N.F. Billups, and L. Diamond Drug absorption II: effect of fasting on intestinal drug absorption J. Pharm. Sci. 58 1969 1200 1202
23. S. Doppenschmitt, H. Spahn-Langguth, C.G. Regårdh, and P. Langguth Role of P-glycoprotein-mediated secretion in absorptive drug permeabiity: an approach using passive membrane permeability and affinity to P-glycoprotein J. Pharm. Sci. 88 1999 1067 1072
24. U. Fagerholm, M. Johansson, and H. Lennernäs Comparison between permeability coefficients in rat and human jejunum Pharm. Res. 13 1996 1336 1342
25. M. Fairstein, R. Swissa, and A. Dahan Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine AAPS J. 15 2013 589 597
26. C. Fernandez-Teruel, I. Gonzalez-Alvarez, V.G. Casabó, A. Ruiz-Garcia, and M. Bermejo Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells J. Drug Target. 13 2005 199 212
27. R. Ferrando, T.M. Ganigues, M.V. Bermejo, R. Martin-Algarra, V. Merino, and A. Polache Effects of ethanol on intestinal absorption of drugs: in situ studies with ciprofloxacin analogs in acute and chronic alcohol-fed rats Alcohol. Clin. Exp. Res. 23 1999 1403 1408
28. I. González-Alvarez, C. Fernández-Teruel, V.G. Casabó-Alós, T.M. Garrigues, J.E. Polli, A. Ruiz-García, and M. Bermejo In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results Biopharm. Drug Dispos. 28 2007 229 239
29. J.S. Kim, S. Mitchell, P. Kijek, Y. Tsume, J. Hilfinger, and G.L. Amidon The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests Mol. Pharm. 3 2006 686 694
30. T. Knutson, P. Fridblom, H. Ahlström, A. Magnusson, C. Tannergren, and H. Lennernäs Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography Mol. Pharm. 6 2009 2 10
31. H. Lennernäs Human jejunal effective permeability and its correlation with preclinical drug absorption models J. Pharm. Pharmacol. 49 1997 627 638
32. H. Lennernäs Human intestinal permeability J. Pharm. Sci. 87 1998 403 410
33. H. Lennernäs Animal data: the contributions of the Ussing chamber and perfusion systems to predicting human oral drug delivery in vivo Adv. Drug Deliv. Rev. 59 2007 1103 1120
34. H. Lennernäs Intestinal permeability and its relevance for absorption and elimination Xenobiotica 37 2007 1015 1051
35. H. Lennernäs Human in vivo regional intestinal permeability: importance for pharmaceutical drug development Mol. Pharm. 11 2014 12 23
36. H. Lennernäs Regional intestinal drug permeation: biopharmaceutics and drug development Eur. J. Pharm. Sci. 2014 (in press)
37. H. Lennernäs, Ö. Ahrenstedt, R. Hällgren, L. Knutson, M. Ryde, and L. Paalzow Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man Pharm. Res. 9 1992 1243 1251
38. H. Lennernäs, J. Crison, and G. Amidon Permeability and clearance views of drug absorption: a commentary J. Pharmacokinet. Biopharm. 23 1995 333 337
39. C. MacLean, U. Moenning, A. Reichel, and G. Fricker Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats Drug Metab. Dispos. 36 2008 1249 1254
40. A. Martín-Villodre, J. Plá-Delfina, J. Moreno, D. Pérez-Buendía, J. Miralles, E. Collado, E. Sánchez-Moyano, and A. del Pozo Studies on the reliability of a bihyperbolic functional absorption model. I. Ring-substituted anilines J. Pharmacokinet. Biopharm. 14 1986 615 633
41. M. Merino, J.E. Peris-Ribera, F. Torres-Molina, A. Sánchez-Picó, M.C. Garćia-Carbonell, V.G. Casabó, A. Martín-Villodre, and J.M. Plá-Delfina Evidence of a specialized transport mechanism for the intestinal absorption of baclofen Biopharm. Drug Dispos. 10 1989 279 297
42. J.M. Miller, A. Dahan, D. Gupta, S. Varghese, and G.L. Amidon Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs J. Control. Release 137 2009 31 37
43. J.A.G. Morais, and M.d.R. Lobato The new European Medicines Agency guideline on the investigation of bioequivalence Basic Clin. Pharmacol. Toxicol. 106 2010 221 225
44. S. Mouly, and M. Paine P-glycoprotein increases from proximal to distal regions of human small intestine Pharm. Res. 20 2003 1595 1599
45. H. Pham-The, T. Garrigues, M. Bermejo, I. González-Álvarez, M.C. Monteagudo, and M.Á. Cabrera-Pérez Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number Mol. Pharm. 10 2013 2445 2461
46. A. Ruiz-GarcIÍa, M. Bermejo, V. Merino, G. Sánchez-Castaño, J. Freixas, and T.M. Garrigues Pharmacokinetics, bioavailability and absorption of flumequine in the rat Eur. J. Pharm. Biopharm. 48 1999 253 258
47. L. Salphati, K. Childers, L. Pan, K. Tsutsui, and L. Takahashi Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man J. Pharm. Pharmacol. 53 2001 1007 1013
48. G. Sánchez-Castaño, A. Ruíz-García, N. Bañón, M. Bermejo, V. Merino, J. Freixas, T.M. Garriguesx, and J.M. Plá-Delfina Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or in vitro partition coefficients: 6-fluoroquinolones J. Pharm. Sci. 89 2000 1395 1403
49. Y. Shirasaka, T. Sakane, and S. Yamashita Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane J. Pharm. Sci. 97 2008 553 565
50. S. Skolnik, X. Lin, J. Wang, X.-H. Chen, T. He, and B. Zhang Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay J. Pharm. Sci. 99 2010 3246 3265
51. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L.X. Yu, and G.L. Amidon A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol. Pharm. 3 2006 631 643
52. M. Thorn, N. Finnstrom, S. Lundgren, A. Rane, and L. Loof Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract Br. J. Clin. Pharmacol. 60 2005 54 60
53. F. Tuʇcu-Demiröz, I. Gonzalez-Alvarez, M. Gonzalez-Alvarez, and M. Bermejo Validation of phenol red versus gravimetric method for water reabsorption correction and study of gender differences in Doluisio's absorption technique Eur. J. Pharm. Sci. 62 2014 105 110
54. M.V.S. Varma, K. Sateesh, and R. Panchagnula Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport Mol. Pharm. 2 2005 12 21
55. O. Wolk, R. Agbaria, and A. Dahan Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development Drug Des. Devel. Ther. 8 2014 1563 1575
56. C. Zimmermann, H. Gutmann, P. Hruz, J.-P. Gutzwiller, C. Beglinger, and J. Drewe Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract Drug Metab. Dispos. 33 2005 219 224
57. M. Zur, M. Gasparini, O. Wolk, G.L. Amidon, and A. Dahan The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol Mol. Pharm. 11 2014 1707 1714
58. M. Zur, A.S. Hanson, and A. Dahan The complexity of intestinal permeability: assigning the correct BCS classification through careful data interpretation Eur. J. Pharm. Sci. 61 2014 11 17